HIT TO LEAD CHEMISTRY UNDER PERFORMANCE AREA 2 OF ID/IQ CONTRACT NO. HHSN271201800001I

这项研究是NIH帮助结束长期成瘾（HEAL）计划的一部分，旨在加速科学解决方案，以了解疼痛的基础并加强临床疼痛管理。 任务订单号75 N95022 F00007倾斜Grace（德克萨斯大学MD安德森分校 癌症中心）- MCSP -命中铅化学（任务订单）），特此授予库里亚 环球公司（承包商）根据ID/IQ合同HHSN 271201800001 I（主合同）。 开展构效关系（SAR）分析与设计、合成、体外吸收、 分布、代谢、排泄和毒理学（ADMET），计算化学/计算机辅助 药物发现（CADD）以及化合物的储存和运输物流，以支持贡献者 格雷斯（得克萨斯大学医学博士安德森癌症中心）在开发一种新的治疗有效， 治疗疼痛这将通过推进其小分子前药的SAR/SPR来实现， 利用它们的分析和体外ADMET开始小分子，以鉴定新的前药。

This study is part of the NIH’s Helping to End Addiction Long-term (HEAL) initiative to speed scientific solutions to understand the basis of pain and enhance clinical pain management. Task Order Number 75N95022F00007 tilted Grace (University of Texas MD Anderson Cancer Center) – MCSP – Hit to Lead Chemistry (Task Order)) is hereby awarded to Curia Global, Inc. (Contractor) under ID/IQ Contract HHSN271201800001I (Parent Contract). to develop structure activity relationship (SAR) analysis and design, synthesis, in vitro absorption, distribution, metabolism, excretion and toxicology (ADMET), computational chemistry/Computer Aided Drug Discovery (CADD), and compound logistics of storage and shipping to support the Contributor Grace (University of Texas MD Anderson Cancer Center) in developing a novel therapeutic effective in treating pain. This will be achieved by advancing the SAR/SPR of their small molecule prodrugs of starting small molecules utilizing their assays and in vitro ADMET to identify novel, prodrugs.